Diurnal hypothalamic-pituitary-adrenal axis measures and inflammatory marker correlates in major depressive disorder

International Journal of Molecular Sciences

Volumn 18, Issue 10, 2017, Pages

  Doolin, Kelly ^a   Farrell, Chloe ^a   Tozzi, Leonardo ^a,b   Harkin, Andrew ^a   Frodl, Thomas ^b   O’Keane, Veronica ^a,c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Cortisol awakening response; Hypothalamic pituitary adrenal axis; Immune system; Inflammation; Major depressive disorder

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CORTISONE; GAMMA INTERFERON; HYDROCORTISONE; INTERLEUKIN 1BETA; MESSENGER RNA; TUMOR NECROSIS FACTOR; 11BETA HYDROXYSTEROID DEHYDROGENASE; BIOLOGICAL MARKER; CYTOKINE;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTISOL AWAKENING RESPONSE; DISEASE ASSOCIATION; ENDOCRINE FUNCTION; FEMALE; GENE EXPRESSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOREGULATION; INFLAMMATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; POLYMERASE CHAIN REACTION; SALIVA ANALYSIS; AREA UNDER THE CURVE; CASE CONTROL STUDY; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SALIVA; YOUNG ADULT;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ADULT; AREA UNDER CURVE; BIOMARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE EXPRESSION; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INTERLEUKIN-1BETA; MALE; MASS SPECTROMETRY; PITUITARY-ADRENAL SYSTEM; RNA, MESSENGER; ROC CURVE; SALIVA; YOUNG ADULT;

EID: 85032455549     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18102226     Document Type: Article

References (67)

1. Arsenault-Lapierre, G.; Kim, C.; Turecki, G. Psychiatric diagnoses in 3275 suicides: A meta-analysis. BMC Psychiatry 2004, 4, 37.
2. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R.; Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62, 593–602.
3. Kessler, R.C.; Zhao, S.; Blazer, D.G.; Swartz, M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J. Affect. Disord. 1997, 45, 19–30.
4. Pariante, C.M.; Lightman, S.L. The HPA axis in major depression: Classical theories and new developments. Trends Neurosci. 2008, 31, 464–468.
5. O'Keane, V.; Frodl, T.; Dinan, T.G. A review of atypical depression in relation to the course of depression and changes in HPA axis organization. Psychoneuroendocrinology 2012, 37, 1589–1599.
6. Farrell, C.; O’Keane, V. Epigenetics and the glucocorticoid receptor: A review of the implications in depression. Psychiatry Res. 2016, 242, 349–356.
7. Fries, E.; Dettenborn, L.; Kirschbaum, C. The cortisol awakening response (CAR): Facts and future directions. Int. J. Psychophysiol. 2009, 72, 67–73.
8. Wust, S.; Wolf, J.; Hellhammer, D.H.; Federenko, I.; Schommer, N.; Kirschbaum, C. The cortisol awakening response—Normal values and confounds. Noise Health 2000, 2, 79–88.
9. Holsboer, F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23, 477–501.
10. Huber, T.J.; Issa, K.; Schik, G.; Wolf, O.T. The cortisol awakening response is blunted in psychotherapy inpatients suffering from depression. Psychoneuroendocrinology 2006, 31, 900–904.
11. Vreeburg, S.A.; Hoogendijk, W.J.; van Pelt, J.; Derijk, R.H.; Verhagen, J.C.; van Dyck, R.; Smit, J.H.; Zitman, F.G.; Penninx, B.W. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: Results from a large cohort study. Arch. Gen. Psychiatry 2009, 66, 617–626.
12. Coutinho, A.E.; Chapman, K.E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 2011, 335, 2–13.
13. Brown, E.S.; Chandler, P.A. Mood and cognitive changes during systemic corticosteroid therapy. Prim. Care Companion J. Clin. Psychiatry 2001, 3, 17–21.
14. Dekker, M.J.; Tiemeier, H.; Luijendijk, H.J.; Kuningas, M.; Hofman, A.; de Jong, F.H.; Stewart, P.M.; Koper, J.W.; Lamberts, S.W. The effect of common genetic variation in 11β-hydroxysteroid dehydrogenase type 1 on hypothalamic-pituitary-adrenal axis activity and incident depression. J. Clin. Endocrinol. Metab. 2012, 97, E233–E237.
15. Slattery, D.A.; Uzunov, D.P.; Cryan, J.F. 11-β hydroxysteroid type 1 knockout mice display an antidepressantlike phenotype in the forced swim test. Acta Neuropsychiatry. 2016, 28, 55–60.
16. Elenkov, I.J.; Webster, E.L.; Torpy, D.J.; Chrousos, G.P. Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: Acute and chronic effects. Ann. N. Y. Acad. Sci. 1999, 876, 1–13.
17. Miura, H.; Ozaki, N.; Sawada, M.; Isobe, K.; Ohta, T.; Nagatsu, T. A link between stress and depression: Shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 2008, 11, 198–209.
18. Sorrells, S.F.; Caso, J.R.; Munhoz, C.D.; Sapolsky, R.M. The stressed CNS: When glucocorticoids aggravate inflammation. Neuron 2009, 64, 33–39.
19. Raison, C.L.; Capuron, L.; Miller, A.H. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27, 24–31.
20. Maes, M. Major depression and activation of the inflammatory response system. Adv. Exp. Med. Boil. 1999, 461, 25–46.
21. Lanquillon, S.; Krieg, J.C.; Bening-Abu-Shach, U.; Vedder, H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22, 370–379.
22. Alesci, S.; Martinez, P.E.; Kelkar, S.; Ilias, I.; Ronsaville, D.S.; Listwak, S.J.; Ayala, A.R.; Licinio, J.; Gold, H.K.; Kling, M.A.; et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: Clinical implications. J. Clin. Endocrinol. Metab. 2005, 90, 2522–2530.
23. Tuglu, C.; Kara, S.H.; Caliyurt, O.; Vardar, E.; Abay, E. Increased serum tumor necrosis factor-α levels and treatment response in major depressive disorder. Psychopharmacology 2003, 170, 429–433.
24. Thomas, A.J.; Davis, S.; Morris, C.; Jackson, E.; Harrison, R.; O'Brien, J.T. Increase in interleukin-1β in late-life depression. Am. J. Psychiatry 2005, 162, 175–177.
25. Taylor, A.E.; Keevil, B.; Huhtaniemi, I.T. Mass spectrometry and immunoassay: How to measure steroid hormones today and tomorrow. Eur. J. Endocrinol. 2015, 173, D1–D12.
26. Kushnir, M.M.; Rockwood, A.L.; Bergquist, J. Liquid chromatography–tandem mass spectrometry applications in endocrinology. Mass Spectrum. Rev. 2010, 29, 480–502.
27. Handelsman, D.J.; Wartofsky, L. Requirement for mass spectrometry sex steroid assays in the journal of clinical endocrinology and metabolism. J. Clin. Endocrinol. Metab. 2013, 98, 3971–3973.
28. Závada, M.; Šafarcik, K.; Topolcan, O. Some problems of radioimmunoassay control. J. Radioanal. Nucl. Chem. 1978, 46, 57–66.
29. Lopez-Duran, N.L.; Kovacs, M.; George, C.J. Hypothalamic-pituitary-adrenal axis dysregulation in depressed children and adolescents: A meta-analysis. Psychoneuroendocrinology 2009, 34, 1272–1283.
30. Kirschbaum, C.; Hellhammer, D.H. Salivary cortisol in psychobiological research: An overview. Neuropsychobiology 1989, 22, 150–169.
31. Edwards, S.; Clow, A.; Evans, P.; Hucklebridge, F. Exploration of the awakening cortisol response in relation to diurnal cortisol secretory activity. Life Sci. 2001, 68, 2093–2103.
32. Hsiao, F.-H.; Yang, T.-T.; Ho, R.T.H.; Jow, G.-M.; Ng, S.-M.; Chan, C.L.W.; Lai, Y.-M.; Chen, Y.-T.; Wang, K.-C. The self-perceived symptom distress and health-related conditions associated with morning to evening diurnal cortisol patterns in outpatients with major depressive disorder. Psychoneuroendocrinology 2010, 35, 503–515.
33. Unschuld, P.G.; Ising, M.; Roeske, D.; Erhardt, A.; Specht, M.; Kloiber, S.; Uhr, M.; Muller-Myhsok, B.; Holsboer, F.; Binder, E.B. Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response. Neuropsychopharmacology 2010, 35, 1583–1592.
34. Knutsson, U.; Dahlgren, J.; Marcus, C.; Rosberg, S.; Bronnegard, M.; Stierna, P.; Albertsson-Wikland, K. Circadian cortisol rhythms in healthy boys and girls: Relationship with age, growth, body composition, and pubertal development. J. Clin. Endocrinol. Metab. 1997, 82, 536–540.
35. Hori, H.; Teraishi, T.; Sasayama, D.; Ozeki, Y.; Matsuo, J.; Kawamoto, Y.; Kinoshita, Y.; Hattori, K.; Higuchi, T.; Kunugi, H. Poor sleep is associated with exaggerated cortisol response to the combined dexamethasone/crh test in a non-clinical population. J. Psychiatr. Res. 2011, 45, 1257–1263.
36. Li, Y.Y.; Hu, Z.Z.; Huang, Z.L.; Yang, S.R. [Role of stress in depression insomnia and sleep characteristics of commonly used animal stress models]. Yao Xue Xue Bao 2012, 47, 1–6.
37. Glozier, N.; Martiniuk, A.; Patton, G.; Ivers, R.; Li, Q.A.; Hickie, I.; Senserrick, T.; Woodward, M.; Norton, R.; Stevenson, M. Short sleep duration in prevalent and persistent psychological distress in young adults: The drive study. Sleep 2010, 33, 1139–1145.
38. Fitzgerald, C.T.; Messias, E.; Buysse, D.J. Teen sleep and suicidality: Results from the youth risk behavior surveys of 2007 and 2009. J. Clin. Sleep Med. 2011, 7, 351–356.
39. Copinschi, G.; Akseki, E.; Moreno-Reyes, R.; Leproult, R.; L’Hermite-Baleriaux, M.; Caufriez, A.; Vertongen, F.; Van Cauter, E. Effects of bedtime administration of zolpidem on circadian and sleep-related hormonal profiles in normal women. Sleep 1995, 18, 417–424.
40. Besnier, E.; Clavier, T.; Castel, H.; Gandolfo, P.; Morin, F.; Tonon, M.C.; Marguerite, C.; Veber, B.; Dureuil, B.; Compère, V. Modulation de l’axe hypothalamo-hypophyso-surrénalien par l’utilisation des agents hypnotiques dans le contexte chirurgical. Ann. Fr. Anesth. Réanim. 2014, 33, 256–265.
41. Stimson, R.H.; Andersson, J.; Andrew, R.; Redhead, D.N.; Karpe, F.; Hayes, P.C.; Olsson, T.; Walker, B.R. Cortisol release from adipose tissue by 11β-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009, 58, 46–53.
42. Mihailova, S.; Ivanova-Genova, E.; Lukanov, T.; Stoyanova, V.; Milanova, V.; Naumova, E. A study of TNF-α, TGF-β, IL-10, IL-6, and IFN- gene polymorphisms in patients with depression. J. Neuroimmunol. 2016, 293, 123–128.
43. Fabbri, C.; Hosak, L.; Mossner, R.; Giegling, I.; Mandelli, L.; Bellivier, F.; Claes, S.; Collier, D.A.; Corrales, A.; Delisi, L.E.; et al. Consensus paper of the wfsbp task force on genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World J. Boil. Psychiatry 2017, 18, 5–18.
44. Dinarello, C.A. Biology of interleukin 1. FASEB J. 1988, 2, 108–115.
45. Van de Veerdonk, F.L.; Netea, M.G. New insights in the immunobiology of IL-1 family members. Front. Immunol. 2013, 4, 167.
46. Dantzer, R.; O'Connor, J.C.; Freund, G.G.; Johnson, R.W.; Kelley, K.W. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9, 46–56.
47. Owen, L.J.; Haslam, S.; Adaway, J.E.; Wood, P.; Glenn, C.; Keevil, B.G. A simplified liquid chromatography tandem mass spectrometry assay, using on-line solid-phase extraction, for the quantitation of cortisol in saliva and comparison with a routine DELFIA method. Ann. Clin. Biochem. 2010, 47, 131–136.
48. Maes, M.; Rief, W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (trycat) pathway. Psychiatry Res. 2012, 196, 243–249.
49. Anisman, H. Cascading effects of stressors and inflammatory immune system activation: Implications for major depressive disorder. J. Psychiatry Neurosci. 2009, 34, 4–20.
50. Pace, T.W.; Hu, F.; Miller, A.H. Cytokine-effects on glucocorticoid receptor function: Relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 2007, 21, 9–19.
51. Bellavance, M.-A.; Rivest, S. The HPA–immune axis and the immunomodulatory actions of glucocorticoids in the brain. Front. Immunol. 2014, 5, 136.
52. Wolkow, A.; Aisbett, B.; Reynolds, J.; Ferguson, S.A.; Main, L.C. Relationships between inflammatory cytokine and cortisol responses in firefighters exposed to simulated wildfire suppression work and sleep restriction. Physiol. Rep. 2015, 3, e12604.
53. Otte, C.; Gold, S.M.; Penninx, B.W.; Pariante, C.M.; Etkin, A.; Fava, M.; Mohr, D.C.; Schatzberg, A.F. Major depressive disorder. Nat. Rev. Dis. Prim. 2016, 2, 16065.
54. Ho, R.C.; Neo, L.F.; Chua, A.N.; Cheak, A.A.; Mak, A. Research on psychoneuroimmunology: Does stress influence immunity and cause coronary artery disease? Ann. Acad. Med. Singap. 2010, 31, 191–196.
55. Stalder, T.; Kirschbaum, C.; Kudielka, B.M.; Adam, E.K.; Pruessner, J.C.; Wust, S.; Dockray, S.; Smyth, N.; Evans, P.; Hellhammer, D.H.; et al. Assessment of the cortisol awakening response: Expert consensus guidelines. Psychoneuroendocrinology 2016, 63, 414–432.
56. Kirschbaum, C.; Hellhammer, D.H. Salivary cortisol in psychoneuroendocrine research: Recent developments and applications. Psychoneuroendocrinology 1994, 19, 313–333.
57. Kirschbaum, C.; Kudielka, B.; Gaab, J.; Schommer, M.; Hellhammer, D. Impact of Gender, Menstrual Cycle Phase, and Oral Contraceptives on the Activity of the Hypothalamus-Pituitary-Adrenal Axis. Psychosom. Med. 1999, 61, 154–162.
58. O’Donnell, K.J.; Bugge Jensen, A.; Freeman, L.; Khalife, N.; O’Connor, T.G.; Glover, V. Maternal prenatal anxiety and downregulation of placental 11β-HSD2. Psychoneuroendocrinology 2012, 37, 818–826.
59. Wyrwoll, C.; Keith, M.; Noble, J.; Stevenson, P.L.; Bombail, V.; Crombie, S.; Evans, L.C.; Bailey, M.A.; Wood, E.; Seckl, J.R.; et al. Fetal brain 11β-hydroxysteroid dehydrogenase type 2 selectively determines programming of adult depressive-like behaviors and cognitive function, but not anxiety behaviors in male mice. Psychoneuroendocrinology 2015, 59, 59–70.
60. Liu, Y.; Ho, R.C.; Mak, A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. J. Affect. Disord. 2012, 139, 230–239.
61. American Psychiatric Association. The Diagnostic and Statistical Manual, 5th ed.; American Psychiatric Publishing: Arlington, VA, USA, 2013.
62. Hamilton, M. A rating scale for depression. J. Nneurol. Neur. Psychiatry 1960, 23, 56–62.
63. Hamilton, M. Rating depressive patients. J. Clin. Psychiatry 1980, 41, 21–24.
64. Radloff, L. The CES-D scale: A self report depression scale for research in the general population. Appl. Psychol. Meas. 1977, 1, 385–401.
65. Buysse, D.J.; Reynolds, C.F., 3rd; Monk, T.H.; Berman, S.R.; Kupfer, D.J. The pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28, 193–213.
66. Bernstein, D.P.; Stein, J.A.; Newcomb, M.D.; Walker, E.; Pogge, D.; Ahluvalia, T.; Stokes, J.; Handelsman, L.; Medrano, M.; Desmond, D.; et al. Development and validation of a brief screening version of the childhood trauma questionnaire. Child Abuse Negl. 2003, 27, 169–190.
67. Fekedulegn, D.B.; Andrew, M.E.; Burchfiel, C.M.; Violanti, J.M.; Hartley, T.A.; Charles, L.E.; Miller, D.B. Area under the curve and other summary indicators of repeated waking cortisol measurements. Psychosom. Med. 2007, 69, 651–659.